Statement from Mark E. Miller on New Insulin Legislation Offered in Senate
WASHINGTON, DC – In light of new insulin legislation offered Wednesday by Sens. Jeanne Shaheen (D‑N.H.) and Susan Collins (R‑Maine), Mark E. Miller, the Executive Vice President of Health Care for Arnold Ventures, issued the following statement:
“The price of insulin absolutely must be addressed. But lowering drug prices piecemeal is not the comprehensive solution Americans need at a time nearly one in four people in this country report difficulty affording a prescription drug.
“Instead, the problem requires a comprehensive approach to achieve meaningful price reductions. Patients and their families struggling to cover the cost of their prescription drugs need Congress to target the fundamental problems in a marketplace that is currently unfair and inefficient.
“It’s time for Congress to tackle the heart of the problem — and finishing its work on a House-passed compromise to allow Medicare to negotiate prescription drug prices will not only provide more comprehensive protections for patients but result in savings to taxpayers and employers.”